Related Experiment Video
Updated: Jun 26, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Olmesartan/Amlodipine: combination therapy for the treatment of hypertension [corrected]
1Department of Hypertension and Nephrology, Dante Pazzanese Institute of Cardiology, SP, Brazil. espimenta@hotmail.com
Insights
Hypertension management is challenging, with many patients not reaching blood pressure goals. Fixed-dose combination therapy, like amlodipine and olmesartan, offers improved blood pressure control and potential organ protection.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Hypertension is a prevalent global health issue and a major risk factor for cardiovascular disease.
- Despite treatment guidelines, a significant majority of hypertensive patients fail to achieve target blood pressure control (<140/90 mmHg).
- Poor medication adherence and the complexity of managing hypertension contribute to the gap between recommended treatment and patient outcomes.
Purpose of the Study:
- To highlight the challenges in achieving blood pressure control in hypertensive patients.
- To emphasize the benefits of combination therapy in hypertension management.
- To discuss the advantages of fixed-dose combination tablets, specifically amlodipine and olmesartan, for improving blood pressure control.
Main Methods:
- Review of current hypertension guidelines and treatment outcomes.
- Analysis of the role of combination therapy in managing hypertension.
- Evaluation of the efficacy and benefits of fixed-dose amlodipine and olmesartan combination therapy.
Main Results:
- Approximately two-thirds of hypertensive patients do not achieve recommended blood pressure goals.
- Combination therapy is recommended for effective blood pressure management.
- Fixed-dose combinations, such as amlodipine/olmesartan, provide synergistic effects for enhanced blood pressure reduction.
Conclusions:
- Achieving blood pressure control remains a significant clinical challenge.
- Fixed-dose combination therapy, particularly with amlodipine and olmesartan, offers a promising strategy for improved hypertension management.
- This combination therapy may lead to better blood pressure control and potential protection of target organs.
Abstract:
Hypertension is a highly prevalent disease and one of the most important modifiable risk factors for cardiovascular disease. Hypertension remains the leading cause of mortality and the third largest cause of disability in both developed and developing countries. Although recent guidelines and advisory statements are recommending lower thresholds and goals for antihypertensive treatment, approximately two thirds of patients do not achieve the goals. In the United States only 36.8% of hypertensive patients achieve the goal of <140/90 mmHg. Poor adherence to antihypertensive medication regimens contributes to the practice-outcome gap. In most hypertensive patients it is difficult or impossible to control blood pressure with one drug, thus current guidelines have recommended the use of combination therapy as first-line treatment, or early in the management of hypertension. Blocking two or more blood pressure regulatory systems provides a more effective and more physiologic reduction in blood pressure. Fixed-dose combinations offer many advantages over free-drug combinations, such as convenience of use, fewer adverse events, and greater antihypertensive potency. Similar to other combinations, fixed-dose combination tablets containing the dihydropyridine calcium channel blocker amlodipine and the angiotensin receptor blocker olmesartan bring together two distinct and complementary mechanisms of action, resulting in improved blood pressure control and potential for improved target organ protection relative to either class of agent alone.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics